ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1 infection. We therefore investigated the level of plasma HIV-1 RNA in patients with viremia suppressed to less than 50–75 copies/ml on standard protease inhibitor- or non-nucleoside reverse transcriptase inhibitor-containing antiretroviral therapy using a new, real-time PCR-based assay for HIV-1 RNA with a limit of detection of one copy of HIV-1 RNA. Single copy assay results revealed that >80% of patients on initial antiretroviral therapy for 60 wk had persistent viremia of one copy/ml or more with an overall median of 3.1 copies/ml. The level of viremia correlated with pretherapy plasma HIV-1 RNA but not with the specific treatment regimen. Longitudinal studies revealed no significant decline in the level of viremia between 60 and 110 wk of suppressive antiretroviral therapy. These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy.

[1]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[2]  Alan S. Perelson,et al.  In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months , 2003, Journal of Virology.

[3]  F. Hecht,et al.  Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 , 2000, Journal of Clinical Microbiology.

[4]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[5]  G. Beall,et al.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.

[6]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[7]  J. Montaner,et al.  Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. , 2004, The Journal of infectious diseases.

[8]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[9]  A. Hsu,et al.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.

[10]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[11]  R. Siliciano,et al.  A long-term latent reservoir for HIV-1: discovery and clinical implications. , 2004, The Journal of antimicrobial chemotherapy.

[12]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[13]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[14]  D. Kempf,et al.  Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. , 2005, The Journal of infectious diseases.

[15]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[16]  F. Mammano,et al.  Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 Variants , 2003, Journal of Virology.

[17]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[18]  R. Dewar,et al.  Comparison of the Quantiplex Version 3.0 Assay and a Sensitized Amplicor Monitor Assay for Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Samples , 1999, Journal of Clinical Microbiology.

[19]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[20]  D. Dimitrov,et al.  Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy , 2001, The Lancet.

[21]  Mario Clerici,et al.  Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.

[22]  Jaap Goudsmit,et al.  Ongoing HIV dissemination during HAART , 1999, Nature Medicine.

[23]  M. Nowak,et al.  Pre–existence and emergence of drug resistance in HIV–1 infection , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[24]  Alan S Perelson,et al.  Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication , 2004, Journal of acquired immune deficiency syndromes.

[25]  S. Hughes,et al.  Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors , 1987, Journal of virology.

[26]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[27]  Yang Wang,et al.  Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[28]  M A Nowak,et al.  Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.

[29]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[30]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[31]  R. Pomerantz,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.